Mixonix, a Farmingdale, New York company that focuses on ultrasonic devices for surgical applications, including osteotomies and debridements, landed European CE Mark approval for its Nexus surgical platform. The system was FDA cleared earlier this year.
The Nexus combines the capabilities of Mixonix’s three existing products, namely BoneScalpel, SonicOne and Sonastar, into a single system that can be used to perform tumor resections, bone corrections, and a variety of other procedures.
The Nexus is designed to accommodate future ultrasonic devices that Mixonix expects to develop. It is powered by the firm’s unique algorithm that has been tuned to deliver high power and high efficiency. This allows for faster resections, particularly when working on bone removals.
Mixonix touts the system’s easy touchscreen interface that lets clinicians prepare for and perform procedures quickly.
“Nexus marks an important leap forward for our Company, as we are bringing to market a powerful and highly integrated, easy-to-use system that we are confident will benefit both healthcare providers and patients by incorporating the latest advances in ultrasonic technology for increased efficiency and efficacy,” said Stavros Vizirgianakis, President and Chief Executive Officer of Misonix, in a press release. Given the important benefits Nexus brings to both physicians and patients, we are confident that our ability to enter the European market will help deliver improved outcomes for treatments across spine surgery, neurosurgery, orthopedic surgery, cosmetic surgery, laparoscopic surgery, and other surgical and medical applications.”
Product page: Nexus…